1. Home
  2. BIPC vs WGS Comparison

BIPC vs WGS Comparison

Compare BIPC & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brookfield Infrastructure Corporation

BIPC

Brookfield Infrastructure Corporation

HOLD

Current Price

$41.35

Market Cap

5.9B

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$71.89

Market Cap

2.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIPC
WGS
Founded
2019
2017
Country
United States
United States
Employees
N/A
1300
Industry
Marine Transportation
Retail: Computer Software & Peripheral Equipment
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
2.6B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BIPC
WGS
Price
$41.35
$71.89
Analyst Decision
Hold
Strong Buy
Analyst Count
1
7
Target Price
$53.00
$140.71
AVG Volume (30 Days)
639.4K
684.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.24%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.93
$29.98
Revenue Next Year
$5.51
$24.85
P/E Ratio
N/A
$1,251.58
Revenue Growth
N/A
N/A
52 Week Low
$32.08
$55.17
52 Week High
$51.72
$170.87

Technical Indicators

Market Signals
Indicator
BIPC
WGS
Relative Strength Index (RSI) 25.03 35.69
Support Level $39.17 $68.55
Resistance Level $41.36 $76.21
Average True Range (ATR) 1.49 5.34
MACD -0.72 -0.11
Stochastic Oscillator 0.88 12.45

Price Performance

Historical Comparison
BIPC
WGS

About BIPC Brookfield Infrastructure Corporation

Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom and the United States.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: